

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

08 Jun 2026

### Evaluation of the effect of 0/3% Pilocarpine mouthwash on xerostomia in diabetic patients with xerostomia

#### Protocol summary

##### Study aim

Evaluation of the effect of 0/3 percent Pilocarpine mouthwash on xerostomia in diabetic patients with xerostomia, presented to Kerman Shahid Bahonar hospital diabetes center in year 1402

##### Design

Clinical trial with control group, triple blinded, crossover groups, phase 3 on 80 patients. Randomized by simple randomization method by the way of shuffling 80 similar cards 40 marked with code A and 40 with B.

##### Settings and conduct

Sampling is done by convenience method. Researchers attend the diabetes center and explain the conditions of the project. If the inclusion criteria exists, people will be included after obtaining written informed consent. The sample is divided into intervention and control groups with randomization and desired variables will be checked and recorded. For blinding, 80 medicated and 80 placebo mouthwashes with similar appearance will be coded with arbitrary codes A and B, by a person (employee of the Oral Diseases Department of Kerman Dental School) who doesn't benefit from the study. All patients, clinical caregivers, researchers, outcome assessors and data analysts will be blinded to the codes related to mouthwashes.

##### Participants/Inclusion and exclusion criteria

The sample consists of 80 over 18-year-old patients referred to Diabetes Center of Kerman Bahonar Hospital. The inclusion criteria are diabetes mellitus (according to the American Diabetes Association), dry mouth (according to the Fox questionnaire), willingness and ability to cooperate correctly. History of uncontrolled asthma, gastric ulcer, autoimmune disease, use of drugs affecting the amount of saliva and dry mouth, HIV, hepatitis B and C infections and unwillingness to cooperate are criteria for not entering.

##### Intervention groups

Intervention group receives 0.3% pilocarpine mouthwash and control group receives placebo mouthwash.

#### Main outcome variables

Severity of xerostomia ; volume of unstimulated saliva

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220930056061N1**

Registration date: **2023-07-29, 1402/05/07**

Registration timing: **registered\_while\_recruiting**

Last update: **2023-07-29, 1402/05/07**

Update count: **0**

##### Registration date

2023-07-29, 1402/05/07

##### Registrant information

##### Name

Shayan Shakeri

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 34 3213 4086

##### Email address

shayan.shakeri@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-07-26, 1402/05/04

##### Expected recruitment end date

2023-08-09, 1402/05/18

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the effect of 0/3% Pilocarpine mouthwash on xerostomia in diabetic patients with xerostomia

**Public title**

Effect of Pilocarpine mouthwash on diabetic patients xerostomia

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Having diabetes mellitus according to the diagnostic criteria of the American Diabetes Association Suffering from dry mouth according to the diagnosis based on the questionnaire of Fox et al desire and physical and mental ability to cooperate and use mouthwash correctly

**Exclusion criteria:**

History of uncontrolled asthma History of gastric ulcer Reluctance to cooperate with the study Acute or chronic use of medicine or mouthwash used to relieve dry mouth History of autoimmune disease Head and neck radiation therapy Infection with human immunodeficiency virus(HIV), hepatitis type B and hepatitis type C using of drugs effecting on the amount of saliva during the trial

**Age**

From **18 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **80**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization is done by simple randomization method. The desired method is done by punching 80 cards with the same appearance, which contain the necessary information to cooperate in the project along with the code related to the group of participants. According to the design of the study, 40 of the cards are coded as A and the other 40 are coded as B. In order to hide the random allocation, the cards are placed in the same opaque sealed envelopes, and after determining the group of each participant, the opened envelope is removed from the sequence. At the time of registration of eligible study participants and after obtaining informed consent, one of the envelopes is allocated to each person, which determines the participant's group. The sequence of random cards and the sealing of card envelopes are done by the researcher Mr. Mohammad

Shayan Shakri, and in order to reduce the possible distortions caused by the knowledge of the researchers about the intervention groups, all researchers are blinded. Due to the cross-over design of the study, the randomization sequence was determined only for the initiation treatment.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

At the beginning of the study, 80 pieces of drug mouthwash (pilocarpine) and 80 pieces of placebo mouthwash that were prepared in the same color with the same taste and smell in the same packaging and volume were prepared in two separate groups to one person (from the employees of the oral diseases department of the Kerman Faculty of Dentistry) , which is without profit and knowledge of the conditions and results of the study, is delivered, which are coded by them with arbitrary codes A and B. Allocation of mouthwash to the participants is done by randomization according to the mentioned method and based on the study design. All participating patients, clinical caregivers, researchers, outcome assessors and data analysts will not know the type of mouthwash used by people (medicinal or placebo) and the code related to the type of mouthwash. After the implementation and completion of the study and analysis of the results, the knowledgeable person responsible for coding the mouthwashes reveals the type of mouthwash corresponding to each code.

**Placebo**

Used

**Assignment**

Crossover

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Kerman University of medical science

**Street address**

Kerman University of medical science research and technology department, Ebn e Sina Ave., Somayeh four-way

**City**

Kerman

**Province**

Kerman

**Postal code**

7619813159

**Approval date**

2023-02-13, 1401/11/24

**Ethics committee reference number**

IR.KMU.REC.1401.513

## Health conditions studied

### 1

#### Description of health condition studied

Dry mouth(xerostomia)

#### ICD-10 code

K11.7

#### ICD-10 code description

Disturbances of salivary secretion

## Primary outcomes

### 1

#### Description

Unstimulated saliva volume of the sample

#### Timepoint

before the start of the intervention, and 14 and 35 days after using mouthwash

#### Method of measurement

Saliva draining method, which is one of the simple and practical methods of measuring the volume of non-irritating saliva in studies, in this method, the person is asked to first wash his mouth with distilled or deionized water to empty it of small debris, then swallow the remaining saliva in their mouth and rest for five minutes, then sit in a quiet environment free of factors that stimulate or limit the secretion of saliva, bend their head down and spit the saliva collected in their mouth for 5 minutes from their lower lip into a 50 ml graduated test container (which has been accurately weighed and sterilized).

### 2

#### Description

Intensity of xerostomia based on self-report of people

#### Timepoint

before the start of the intervention, and 14 and 35 days after using mouthwash

#### Method of measurement

Patients' self-reported questionnaire

### 3

#### Description

Intensity of xerostomia based on Fox questionnaire

#### Timepoint

before the start of the intervention, and 14 and 35 days after using mouthwash

#### Method of measurement

Fox et. al questionnaire

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: It is recommended for every person to keep 3 ml of 0/3% Pilocarpine mouthwash for 2 weeks in 3 meals a day (preferably after meals) in their mouth for 1 minute each time and then throw it away.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: For 2 weeks, it is recommended for each person to use a placebo mouthwash consisting of the mouthwash excipients under study, which is prepared by essential oil in the same color with the same taste and smell in the same packaging and volume, in 3 meals a day (preferably after meals) ) and keep 3 ml in your mouth for 1 minute each time and then throw it away.

#### Category

Placebo

### 3

#### Description

Control group: consists of the (remaining) people of the primary intervention group. due to the crossover design of the study, after the end of the washout period, it is recommended from each person of this group to take placebo mouthwash consisting of the excipients of the studied mouthwash which is prepared in same color, smell, essence in the same packaging and volume, for 2 weeks 3 meals a day (preferably after meals) and keep 3 ml in mouth for 1 minute each time and then throw it away.

#### Category

Placebo

### 4

#### Description

Intervention group: consists of the (remaining) people of the primary control group. due to the crossover design of the study, after the end of the washout period, it is recommended from each person of this group to take Pilocarpine mouthwash for 2 weeks in 3 meals a day (preferably after meals) in their mouth for 1 minute each time and then throw it away.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Bahonar Hospital Diabetes Center, Kerman city

##### Full name of responsible person

Dr.Soosan Hajipoor

##### Street address

Shahid Sepahbod Qarani St, Kerman city, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7613747181

**Phone**

+98 34 3223 5011

**Email**

bahonarhospitalresearch@gmail.com

**Web page address**

https://bh.kmu.ac.ir/

## Sponsors / Funding sources

### 1

**Sponsor**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Dr. Reza Malek Pourafshar

**Street address**

Kerman University of Medical science, Haft bagh alavi  
blvd., Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913555

**Phone**

+98 34 3132 5700

**Email**

KMU\_RESEARCH@YAHOO.COM

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kerman University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Mohammad Shayan Shakeri

**Position**

Student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dentistry

**Street address**

28th Alley, Shahid Sadooghi Blvd., Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7618843663

**Phone**

+98 34 3213 4086

**Email**

shayan.shakeri@yahoo.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Mohammad Shayan Shakeri

**Position**

Last year dental Student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dentistry

**Street address**

28th Alley, Shahid Sadooghi Blvd., Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7618843663

**Phone**

+98 34 3213 4086

**Email**

shayan.shakeri@yahoo.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Mohammad Shayan Shakeri

**Position**

Last year student of Dentistry

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dentistry

**Street address**

28th Alley, Shahid Sadooghi Blvd., Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7618843663

**Phone**

+98 34 3213 4086

**Email**

shayan.shakeri@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available